<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093338</url>
  </required_header>
  <id_info>
    <org_study_id>P025</org_study_id>
    <nct_id>NCT02093338</nct_id>
  </id_info>
  <brief_title>L.Fermentum CECT5716 in Treatment of Breast Pain</brief_title>
  <official_title>Study of Intervention Nutritional, Multicenter, Randomized, Blind, Parallel Group to Evaluate the Efficacy of Lactobacillus Fermentum CECT5716 to Reduce the Load Bacterial in Potential Pathogens in Milk of Mothers With Breast Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosearch S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Funding: The Agency of Innovation and Development of Andalusia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Statistical analysis: SEPLIN Soluciones Estadísticas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biosearch S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this intervention study is to evaluate the efficacy of Lactobacillus&#xD;
      fermentum CECT5716 to reduce the presence in the milk of genera Staphylococcus and&#xD;
      Streptococcus as risk factors for mastitis in women with breast pain&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Type of study Nutritional intervention study, multicenter, randomized, blinded, parallel&#xD;
           group included 25 women per group&#xD;
&#xD;
             -  Group 1: 3x109 cfu / day (n = 25)&#xD;
&#xD;
             -  Group 2: 6x109 cfu / day (n = 25)&#xD;
&#xD;
             -  Group 3: 9x109 cfu / day (n = 25)&#xD;
&#xD;
             -  Group 4: placebo (n = 25)&#xD;
&#xD;
        2. Statistical calculation of sample size. The calculation of sample size was calculated by&#xD;
           the company SEPLIN Solutions Statistics. The primary endpoint was the bacterial count of&#xD;
           in milk. The sample size obtained to observe a difference of 1 log10, with a power of&#xD;
           0.80 and a significance level of 0.05 was 20 volunteers per group.&#xD;
&#xD;
        3. Randomization Randomization was performed using a list of random numbers generated by&#xD;
           computer. Subjects will be randomized in a strictly sequential.&#xD;
&#xD;
           If a subject is removed from the test, the number that was assigned randomization not be&#xD;
           reused again.&#xD;
&#xD;
        4. Overall design and outline of the study At visit 1 we require the informed consent of&#xD;
           the patient. It will take the milk sample, we will review the implementation of the&#xD;
           inclusion and exclusion criteria. Be randomized and explain the treatment guidelines to&#xD;
           be followed, the data to be collected and medical appointments that must go (2 and 3&#xD;
           weeks). It will complete the pain assessment questionnaire (MQP) and nutrition survey.&#xD;
&#xD;
           On visits 2, 3 and 4 corresponding to 1, 2 and 3 weeks of intervention will collect milk&#xD;
           sample pain assessment survey and nutrition survey.&#xD;
&#xD;
           Milk samples (5 mL) were collected aseptically in sterile tubes to be frozen immediately&#xD;
           until analysis to be carried out within seven days.&#xD;
&#xD;
        5. Intervention duration The intervention will last three weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Staphylococcus count at 3 weeks</measure>
    <time_frame>0, 3 weeks</time_frame>
    <description>Counts of Staphylococcus in breast milk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Streptococcus counts at 3 weeks</measure>
    <time_frame>0, 3 weeks</time_frame>
    <description>Streptococcus counts in breast milk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Breast pain score at 3 weeks</measure>
    <time_frame>0, 3 weeks</time_frame>
    <description>evaluation of breast pain</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Breast Pain</condition>
  <arm_group>
    <arm_group_label>fermentum 3x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus fermentum CECT5716 at 3x10e9 cfu/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fermentum 6x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus fermentum CECT5716 at 6x10e9cfu/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fermentum 9x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus fermentum CECT5716 at 9x10e9cfu/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus fermentum CECT5716</intervention_name>
    <arm_group_label>fermentum 3x</arm_group_label>
    <arm_group_label>fermentum 6x</arm_group_label>
    <arm_group_label>fermentum 9x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator: maltodextrin</intervention_name>
    <description>Placebo</description>
    <arm_group_label>maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        · breast-feeding women&#xD;
&#xD;
          -  Swelling and / or warmth in the chest&#xD;
&#xD;
          -  Chest pain&#xD;
&#xD;
          -  total bacteria count in milk greater than or equal to 3 log10 colony forming units&#xD;
             (CFU) / mL,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  breast abscesses, Raynaud syndrome,&#xD;
&#xD;
          -  Antibiotic treatment&#xD;
&#xD;
          -  Allergic to antibiotics&#xD;
&#xD;
          -  Low expectation of compliance with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Miguel A Díaz López, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecology Service of Virgen de las Nieves Hospital, Granada (Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast pain</keyword>
  <keyword>probiotic</keyword>
  <keyword>mastitis</keyword>
  <keyword>lactobacillus fermentun</keyword>
  <keyword>Staphylococcus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastodynia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

